ZYBT (Zhengye Biotechnology Holding) Moat Score: 4/10 (As of Aug. 25, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZYBT Zhengye Biotechnology Holding Ltd ZYBT
20 GF Score
Price $1.93
! 5 Warning Signs
View Full Analysis

What is Zhengye Biotechnology Holding Moat Score?

Zhengye Biotechnology Holding ZYBT -1.03% 20 Moat Score is 4 as of Aug. 25, 2026. GuruFocus rates ZYBT with a GF Score™ of 20/100. The stock has 5 warning signs investors should review. Among 1,025 Drug Manufacturers companies, Zhengye Biotechnology Holding ranks better than 90.73% on this metric.

Zhengye Biotechnology Holding has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Zhengye Biotechnology Holding has Narrow Moat: Zhengye Biotechnology Holding Ltd has a modest moat due to its proprietary technology and some intellectual property. However, it lacks strong brand recognition and customer loyalty. The company benefits from some economies of scale, but faces significant competition and limited pricing power.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Zhengye Biotechnology Holding might have Narrow Moat - Discernible but modest moat.

Zhengye Biotechnology Holding  (NAS:ZYBT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Zhengye Biotechnology Holding Moat Score Related Terms

ZYBT vs TLPH, CPHI, CPIX: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Zhengye Biotechnology Holding's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zhengye Biotechnology Holding Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Zhengye Biotechnology Holding's Moat Score distribution charts can be found below:

* The bar in red indicates where Zhengye Biotechnology Holding's Moat Score falls into.


ZYBT
20GF Score
Zhengye Biotechnology Holding Ltd ZYBT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Zhengye Biotechnology Holding (ZYBT) has a Moat Score of 4 as of Aug. 25, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Zhengye Biotechnology Holding ranks #95 out of 1025 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is Zhengye Biotechnology Holding's Moat Score too high?
Zhengye Biotechnology Holding's current Moat Score is 4. Based on the distribution chart, Zhengye Biotechnology Holding ranks #95 out of 1025 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Zhengye Biotechnology Holding has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Zhengye Biotechnology Holding's Moat Score compare to TLPH and CPHI?
According to the Drug Manufacturers industry distribution chart, Zhengye Biotechnology Holding ranks #95 out of 1025 companies for Moat Score. This places Zhengye Biotechnology Holding in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Zhengye Biotechnology Holding's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhengye Biotechnology Holding stock overvalued right now?
Zhengye Biotechnology Holding (ZYBT) has a current Moat Score of 4. The current Moat Score is 4. Zhengye Biotechnology Holding's overall GF Score™ is 20/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Zhengye Biotechnology Holding (ZYBT), the current Moat Score is 4 as of Aug. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zhengye Biotechnology Holding Business Description

Address No. 1 Lianmeng Road, Jilin Economic & Technical Development Zone, Jilin Province, Jilin City, CHN
Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has a diverse range of vaccines, including vaccines for swine, cattle, goats, waterfowl, sheep, poultry, and pets, available in various provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt. The company generates maximum revenue from the sale of swine vaccines, followed by poultry and other vaccines.
20GF Score

Get the complete analysis for ZYBT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.93
Price